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Introduction
To date, there have been no systematic treatment studies 
on subjects with presenilin (PSEN) mutations [1] who 
inherit an autosomal dominant form of early onset 
familial Alzheimer’s disease (AD). Th   e principal objective 
of this review is to summarize the existing published pilot 
studies that address the issues of presymptomatic 
intervention in early onset familial AD and to compare 
these results with analogous treatment studies in hyper-
lipidemic subjects who are heterozygous for apolipo-
protein Eε4 (ApoEε4). Our decision to focus on studies of 
presymptomatic rather than symptomatic subjects was 
based on the premise that most putative therapies for AD 
are likely to have more demonstrable eﬀ  ects on normal 
subjects compared to those with overt AD whose brains 
have already been subject to extensive neurodegenerative 
changes. We also recognize that it is not yet known 
whether any preventative opportunities that may arise as 
a consequence of an understanding of the pathogenesis 
of PSEN1 mutations will be applicable to the vastly larger 
number of cases of mild cognitive impairment and late 
onset AD (LOAD).
Both groups of subjects exhibit early increased brain 
deposition of amyloid-beta 42 (Aβ42),  which many 
researchers [2,3] have proposed is either a direct or 
intermediary toxic agent in the genesis of the neuro-
degeneration that subsequently leads to AD. Homo-
zygotes for ApoEε4 are at far greater risk for late onset 
AD than are heterozygotes, but we did not identify a 
suﬃ   ciently large enough group of the former to comprise 
a separate study group. Decreases in cerebral spinal ﬂ  uid 
(CSF) Aβ42 levels precede cognitive decline in subjects 
with  PSEN1 mutations [4,5]. Consequently, in these 
subjects there is a window of opportunity - estimated as 
at least 4 to 12 years - to evaluate the ability of any 
putative prophylactic therapy to decrease, arrest or 
reverse abnormalities in Aβ42 metabolism many years 
before clinical symptoms of AD occur. For example, 
increased levels of CSF phospho-tau and total tau, which 
are direct measurements that neurodegeneration is 
Abstract
Because cerebrospinal fl  uid (CSF) abnormalities in 
presymptomatic subjects with PSEN1 (presenilin 1) 
mutations may be observed 4 to 12 years prior to the 
estimated age at onset, it is possible to test putative 
therapies on the CSF analytes that correlate with 
neurodegeneration during this presymptomatic 
window of clinical opportunity. It is also possible to 
test the same therapy on a comparison group with 
increased risk status conferred by both hyperlipidemia 
and heterozygosity for apolipoprotein Eε4. To our 
knowledge, the only putative therapy thus far tested 
in such a common design has been statin therapy. The 
results of these tests show increases in soluble amyloid 
precursor protein (sAPP)α correlating with statin-
induced decreases in serum cholesterol levels in the 
non-PSEN1 subjects. This result could be one functional 
correlate for part of the substantial risk reduction for 
late onset Alzheimer’s disease recently reported in the 
Rotterdam study, a large, long-term prospective statin 
trial. Statin therapy signifi  cantly decreased both sAPPα 
and sAPPβ in presymptomatic PSEN1 subjects. Initially, 
elevated phospho-tau levels in PSEN1 subjects did 
not further increase during the 2 to 3 years of statin 
therapy, possibly indicative of a prophylactic eff  ect. 
These results suggest that large and longer term trials 
of statin therapy correlating changes in CSF biomarker 
levels with clinical course may be warranted in both 
presymptomatic PSEN1 and non-PSEN1 subjects.
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PSEN1 carriers [4,5].
Epidemiological and interventional studies of 
statins and Alzheimer’s disease
Over a decade ago, retrospective epidemiological studies 
strongly suggested that statin therapy reduced the risk of 
LOAD [6,7]. More recently, the prospective Rotterdam 
study [8], which included 6,992 participants followed for 
a mean of 9 years, has reported that statin therapy sub-
stan  tially reduced the risk of LOAD by almost 50%. 
Several recent studies of large cohorts have reached 
similar conclusions [9,10]. However, contrary ﬁ  ndings 
were found in other large epidemiological studies [11-
13]. Methodological diﬀ  erences and the time and extent 
of the clinical assessments may account for some of these 
conﬂ   icting results and their interpretations [8,14]. 
Prospective studies failing to report a protective eﬀ  ect of 
statins tended to be characterized by limited durations of 
follow-up, often 3 years or less, to have a lower number 
of incident cases and sometimes inclusion of older 
subjects than in those studies reporting protective eﬀ  ects 
[8,14].
However, assuming that these protective eﬀ  ects  of 
statins are genuine, it is not yet clear how statins may 
produce such eﬀ  ects and whether they are more related 
to the lipid lowering eﬀ   ects of statins or to the 
‘pleiotropic’ eﬀ  ects of statins. Such non-lipid eﬀ  ects of 
statins with respect to possible risk-reduction of LOAD 
include the improvement of endothelial function, the 
reduction of reactive oxygen species and the suppression 
of inﬂ   ammatory reactions [15,16]. Nor is there yet a 
consensus as to whether statins with a greater lipo-
philicity are associated with increased therapeutic bene-
ﬁ  t. However, the Rotterdam study [8] showed that the 
protective eﬀ  ects are independent of statin lipophilicity, 
although there was no reported comparison of the eﬀ  ects 
of atorvastatin with those of simvastatin, which is the 
more lipophilic of these two statins.
Mechanisms of putative benefi  ts of statins in 
Alzheimer’s disease
Other work [17] has suggested that the putative beneﬁ  ts 
of statins may be attributed to a decrease in cholesterol 
levels in cellular membranes that would increase mem-
brane ﬂ   uidity so as to permit α-secretase to cleave 
amyloid precursor protein (APP) along non-amyloido-
genic pathways. Th  is would reduce the production of 
soluble APPβ (sAPPβ) that, in turn, would decrease the 
amount of substrate available for conversion by γ-
secretase to Aβ42, which is assumed by many to be an 
agent within a cascade eventually responsible for neuro-
degeneration [2,3]. Pilot studies to date on presymp-
tomatic subjects with PSEN1 mutations have also 
assessed the eﬀ   ects of statins as a function of their 
lipophilicity [18], as will be discussed.
Th  e accessible relevant CSF analytes for such studies 
are the neurodegenerative triad of Aβ42, phospho-tau, 
and total tau, as well as the APP cleavage products sAPPα 
and sAPPβ, representing the initial stages of APP 
metabolism, and cholesterol, its precursor lathosterol, 
and its metabolite 24(s)-hydroxycholesterol. Th  ese  lipids 
serve as surrogate markers for changes in brain levels of 
these analytes following statin therapy. Th  e descriptive 
data on our subjects and our experimental results with 
respect to the above analytes have been published [19].
Recruitment of subjects
Subjects with presymptomatic PSEN1 mutations were 
recruited from a large cohort that has participated in our 
studies since 1985 [20]. Aﬀ  ected members of this cohort 
carry the C410Y PSEN1 mutation [1]. Approximately 40 
at-risk members of this cohort were contacted, of whom 
roughly half either had already had presymptomatic 
genetic testing or agreed to such testing. Eight pre-
symptomatic carriers were identiﬁ   ed and six of these 
agreed to participate in the statin studies. Another cohort 
in the Worcester, Massachusetts area with double PSEN1 
mutations (P242H, R352H) was also identiﬁ  ed, but only 
two presymptomatic carriers agreed to participate. 
Eleven non-PSEN1 subjects who were hyperlipidemic 
and who, except for two cases, were heterozygous for 
ApoEε4 also agreed to participate.
Th  ere were hurdles to recruiting subjects that were 
diﬀ  erent in the two cohorts.
A substantial number of at-risk subjects for the PSEN1 
mutation did not wish to know their genetic status, a 
concern expressed by most at-risk subjects in other 
PSEN1 cohorts [21]. In both groups, some subjects 
declined to participate based on their reluctance to 
undergo pre-treatment and post-treatment lumbar punc-
tures. Nevertheless, the obstacle of the limited number of 
participating subjects was partially compensated for by a 
series of observations over time for most PSEN1 subjects 
(6 months, 1 year, 2 years and 3 years after statin treat-
ment in comparison to pre-statin baseline levels). In 
addition, the application of general linear mixed statis-
tical models [18] coupled with the large eﬀ  ects of statins 
over time on some of the tested analytes permitted a 
number of conclusions of robust signiﬁ  cance.
Th  e discovery that CSF abnormalities in neuro  de-
genera  tive markers may occur a decade before clinical 
symptoms occur provides an opportunity to detect the 
eﬀ  ects of a putative treatment on CSF analytes many 
years before a subject would otherwise likely be clinically 
symptomatic. However, that long clinically asymptomatic 
duration is a two-edged sword in the sense that major 
changes in clinical status are unlikely to be easily 
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the average age of risk for a particular kindred. All of our 
subjects maintained normal neuropsychological status 
during the relatively brief period of 3 to 4 years over 
which the studies on CSF analytes were carried out. An 
insuﬃ     cient number of subjects remained in the study 
thereafter to complete longer term assessment of clinical 
status.
Results of statin therapy on CSF lipid levels
All the data on the age, sex, PSEN1 status and APOE 
genotype of our subjects together with statin type and 
dose over time with resultant serum total cholesterol and 
low density lipoprotein levels have been published [19]. 
Additionally, the resultant changes in CSF levels for 
lathosterol, cholesterol and 24(s)-hydroxycholesterol as a 
result of statin treatment have also been reported [19]. 
Th   ese CSF lipid levels reached a minimum at 7 months, a 
return to baseline at 15 months, an overshoot that peaked 
at 24 months and a drop towards baseline at 36 months. 
Th   ere were no diﬀ  erences in the eﬀ  ects of the two statins 
with respect to CSF lipid levels nor in PSEN1 versus non-
PSEN1 subjects.
Statin therapy and APP metabolism
Th  e results of statin therapy on levels of CSF sAPPα, 
sAPPβ, phospho-tau, total tau and Aβ42 [18] are shown 
for non-PSEN1 and PSEN1 subjects in Table 1. Th  e  ﬁ  rst set 
of results - called ‘Primary objectives’ - gives the average 
eﬀ  ects of treatment independent of statin type. Th  ere  was 
a signiﬁ  cant increase in sAPPα of 7% (P = 0.013) in the 
non-PSEN1 subjects and a signiﬁ  cant decrease in sAPPα 
of -16.5% (P = 0.0014) and in sAPPβ of -21.2% (P = 0.0005) 
in the PSEN1 subjects. Th   e decrease of -8.3% in phospho-
tau in the PSEN1 subjects approaches signiﬁ  cance 
(P = 0.076).
When the changes in these same CSF analytes are 
correlated with the speciﬁ  c drugs (‘Drug eﬀ  ect’ columns 
in Table 1), but not with reduction in serum lipid levels, 
all of the signiﬁ  cant changes in sAPPα and sAPPβ in both 
subject groups are associated with simvastatin therapy. 
However, when the data are correlated both with speciﬁ  c 
drug and the extent of reduction in serum lipid levels 
(‘Controlled for lipids’ columns in Table 1), there is a 
signiﬁ  cant increase in sAPPα of 9.6% (P = 0.0082) in the 
non-PSEN1 subjects on atorvastatin and an increase of 
23.7% (P  =  0.0005) for non-PSEN1 subjects on simva-
statin. However, the diﬀ  erence between the two statins 
with regard to increased sAPPα in this subject group was 
not signiﬁ  cant.
In the PSEN1  subjects, there was a reduction in 
sAPPα for the subjects on simvastatin. Moreover, the 
decrease in sAPPβ after simvastatin therapy found when 
not control  ling for serum lipid levels was not signiﬁ  cant 
when we controlled for reduction in serum lipid levels. 
Whether these discordant results indicate that the 
statin-induced reduction in sAPPβ in this subject group 
is not dependent on statin dose nor on the statin dose-
related reduction in serum lipid levels or to other 
factors is not clear.
Th   e above results related to APP metabolism were well 
ﬁ   tted by general linear methods. However, ﬁ  tting  the 
temporally diphasic responses of statin-induced changes 
in CSF lipids required quadratic models. Consequently, it 
is unlikely that the changes observed in the CSF 
biomarkers are dependent upon CSF lipid levels.
Table 1. Eff  ect of statin therapy with simvastatin or atorvastatin on analytes in non-PSEN1 and PSEN1 subjects
  Primary objective  Drug eff  ect  Controlled for lipids
  Statins  Atorvastatin Simvastatin Atorvastatin Simvastatin
Analyte %  change  P-value %  change P-value %  change P-value %  change P-value %  change P-value
Non-PSEN1
  sAPPα  7  0.013  -  NS  13.1 0.019  9.6 0.0082  23.7  0.0005
  sAPPβ  - NS - NS - NS - NS - NS
  Phospho-tau  - NS - NS - NS - NS - NS
  Total  tau  - NS - NS - NS - NS - NS
  AB42  - NS - NS - NS - NS - NS
PSEN1
  sAPPα  -16.5 0.0014  -  NS  -26.5 0.0002  -  NS  -24.1 0.0003
  sAPPβ  -21.2  0.0005  - NS  -31.5  0.0001  - NS - NS
  Phospho-tau  -8.3  0.076  - NS - NS - NS - NS
  Total  tau  - NS - NS - NS - NS - NS
  AB42  - NS - NS - NS - NS - NS
Aβ42 = amyloid-beta 42; NS, not signifi  cant; sAPP, soluble amyloid precursor protein.
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signiﬁ   cant nor were there any signiﬁ   cant changes in 
Aβ42, phospho-tau and total tau.
Eff  ects of statin therapy on CSF analytes
Th  e increase in sAPPα in the non-PSEN1 asymptomatic 
subjects without a corresponding decrease in sAPPβ is at 
ﬁ   rst glance surprising because, in general, it has been 
assumed that enhanced cleavage of APP by α-secretase 
results in a corresponding decrease in sAPPβ because less 
APP would be available as substrate for its generation [22]. 
However, that hypothesis, although apparently correct 
under many circumstances, does not always appear to be 
valid [23,24]. For example, a lack of exclusivity in the 
production of Aβ and sAPPα has been demonstrated in 
multiple human cell lines and in a transgenic mouse model 
in response to various activators [23].
In theory, the increases in sAPPα may be beneﬁ  cial in 
risk-reduction of AD independent of whether there is a 
corresponding decrease in sAPPβ. For example, Kojro 
and colleagues [17] in their initial α-secretase study 
noted that increased sAPPα has trophic eﬀ  ects  [25], 
stimu  lates neurite outgrowth [26], regulates synapto-
genesis [27], stabilizes neuronal calcium homeostasis 
[28], protects hippocampal and cortical neurons against 
the toxic eﬀ  ects of glutamate and AB peptide [29] and 
has memory-enhancing eﬀ  ects in normal and amnestic 
mice [30].
Although our result that there was no change in CSF 
Aβ42 levels, at least for the non-PSEN1 subjects, is at ﬁ  rst 
glance disappointing from a possible therapeutic pers-
pec  tive, it is not surprising given a similar result in 
human subjects with AD [24,31]. However, high doses of 
simvastatin have been shown to reduce both Aβ42 and 
Aβ40 in both the CSF and brain homogenates of guinea 
pig [32]. We have no data on Aβ40 metabolism given that 
all our CSF samples were assayed by Athena Diagnostics 
for Aβ42, phospho-tau and total tau; this laboratory did 
not oﬀ   er assays for Aβ40. Consequently, our lack of 
accessibility to Aβ40 levels also precluded study of the 
eﬀ  ects of statin treatment on Aβ42/Aβ40 ratios.
We do not know whether the oppositely directed 
changes in sAPPα by statins in the PSEN1 and non-
PSEN1 subjects are the consequence of a diﬀ  erent stage 
in the development of clinically presymptomatic neuro-
degeneration in these two groups, whether the mutation 
itself alters the accessibility of cleavage sites for APP 
metabolism, or whether there is greater underlying 
heterogeneity in the non-PSEN1 subjects that favors the 
observed results.
Th  e phospho-tau levels were normal to begin with in 
the non-PSEN1 subjects and were not changed by statin 
therapy. Previous studies [33] observed that simvastatin, 
but not pravastatin, slightly reduced the levels of 
phospho-tau-181 in hypercholesterolemic subjects with-
out dementia. Moreover, statin therapy has been reported 
to reduce neuroﬁ  brillary tangle burden found at autopsy 
[34]. In our studies of PSEN1 subjects, statin therapy 
reduced the phospho-tau values by 8.3% approach  ing 
signiﬁ  cance (P = 0.076) but with no signiﬁ  cant changes in 
total tau or Aβ42.
Nevertheless, the average pre-statin phospho-tau level 
in PSEN1 carriers was already abnormally elevated at the 
onset of our studies and would be expected to have risen 
without treatment during the period of the study. Th  us, 
the result that the phospho-tau levels did not rise during 
the course of our studies may suggest that further tests of 
statins in a larger group of PSEN1 subjects may be 
warranted.
As for the non-PSEN1 subjects, the increases in sAPPα 
after statin therapy are quite substantial and might be 
one of the factors contributing to the decreased risk of 
AD in subjects undergoing long-term statin therapy in 
several recent long-term trials [9-11].
Neurotoxic eff  ects on Aβ42
Th  ere are many potential mechanisms by which Aβ42 
may lead to downstream neurodegeneration. Th  ese in-
clude direct neurotoxicity [2,3], direct vascular endo  the-
lial dysfunction [35] and neuroinﬂ   ammation [36]. Th  e 
direct neurotoxic aﬀ  ects of Aβ42 oligomers [2,3] include 
reductions in glutamatergic synaptic transmission and 
plasticity and attenuation of excitatory synaptic 
transmission by decreasing the number of surface AMPA 
and NMDA receptors associated with a collapse of gluta-
matergic dendritic spines.
At present, it does not seem possible to detemine the 
relative neurotoxicities of the various eﬀ  ects of Aβ42 and 
their relative contributions could diﬀ  er depending on the 
stage of disease. However, even if statin therapy does not 
decrease sAPPβ and Aβ42 in non-PSEN1 subjects, there 
remains the possibility that increases in α-secretase 
activity activate a pathway that substantially reduces the 
neurotoxicity of Aβ42.
Th  ere is a possible relationship between our ﬁ  ndings 
and recent work on a connection between cellular prion 
protein (PrPc) and Aβ42 metabolism [37-38]. For example, 
PrPc has been reported to mediate the impairment of 
synaptic plasticity by Aβ oligomers [37]. According to 
these authors, the blockade of long-term potentiation 
may be rescued by anti-PrP antibodies that prevent Aβ 
oligomers from binding to PrPc [38]. Th  ese studies [37-
38] conclude that PrPc is a mediator of Aβ oligomer-
induced synaptic dysfunction and that PrPc-speciﬁ  c 
pharmacologic interventions may have therapeutic 
poten  tial for the treatment of AD. Moreover, studies of 
memory impairment in a mouse model of AD have found 
that the deletion of PrPc expression dissociated Aβ 
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suggesting that the cognitive deﬁ  cit normally resulting 
from some aspect of the Aβ42 cascade selectively 
requires PrPc [39].
However, even more recently, three groups [40-42] 
studying diﬀ  erent model systems from those utilized by 
the above authors, although conﬁ  rming the high avidity 
of Aβ42 for PrPc, failed to conﬁ  rm any reduction in the 
neurotoxicity of Aβ42 in the absence of its binding to 
PrPc. Clearly, it would be of great interest if it could be 
determined whether the original results apply to humans. 
Moreover, α-secretase has been reported to be respon-
sible for the physiological processing of PrPc in the 
middle of its toxic sequence [43-45]. Th  us, Cisse and 
Mucke [45] suggest that one way to prevent both Aβ 
production and the downstream mediation of PrPc might 
be to increase α-secretase activity. We suggest the possi-
bility that a statin-induced increase in α-secretase activity 
could, assuming that the Aβ42-PrPc link for the 
neurotoxicity of Aβ42 applies in humans, lead to the 
reduction of the neurotoxicity of Aβ42 even if its concen-
tration was not reduced. Th  us, our recent ﬁ  ndings 
preceding publications about the proposed link between 
Aβ42 oligomers and PrPc (together with their cleavage by 
α-secretase) may take on added signiﬁ  cance, at least for 
the reduction of AD risk in non-PSEN1 subjects, depend-
ing upon the outcome of the Aβ42-PrPc controversy.
Moreover, other agents increase the production of α-
secretase, at least in cell lines. For example, both 
testosterone [46] and estradiol [47] increase the secretion 
of the non-amyloidogenic APP fragment, sAPPα, and 
decrease the secretion of Aβ peptides. It would be of 
great interest to know whether testosterone and estradiol 
have similar actions in human males and females, 
respectively, for carriers of PSEN1 mutations as well as 
for carriers of ApoEε4 alleles.
It is also well established that mid-life serum total 
cholesterol levels are associated with an increased risk of 
both AD and vascular dementia [48]. Clearly, dementia 
risk factors are best addressed well before disease 
symptoms appear. While there is strong evidence that 
these conclusions apply to non-PSEN1 subjects, it is 
important to know whether or not they apply to PSEN1 
subjects as well.
Although this review has focused on the relationship of 
putative statin therapy with excess Aβ42 assumed to be 
part of the cascade that leads to neurodegenerative 
factors, pleiotropic eﬀ  ects of statins must be considered. 
For example, others have suggested that the putative 
beneﬁ  cial  eﬀ   ects of statins might be through the 
production of nitric oxide at the microvascular 
endothelial level [5]. Moreover, a recent study suggests 
that mutations in PSEN1 genes may produce defective 
lyso  somal proteolysis, which could itself represent a basis 
for pathologic protein accumulations in neuronal cell 
death leading to the identiﬁ  cation of novel therapeutic 
targets [49].
Conclusion
Long-term statin therapy in non-PSEN1 hyperlipidemic 
subjects largely heterozygous for ApoEε4 produced 
substantial increases in CSF sAPPα. It would be of great 
interest to know whether this eﬀ   ect, if conﬁ  rmed  in 
larger studies, contributes to the substantial reduction of 
risk of AD shown in several large and long-term pros  pec-
tive studies [24].
It would also be of great interest to know whether 
presymptomatic subjects with PSEN1 mutations would 
experience beneﬁ   cial clinical results given our ﬁ  nding 
that statins decreased sAPPβ in such subjects, and that 
initially elevated CSF phospho-tau levels did not further 
rise over the 2 to 3 years of statin therapy.
It is the hope of many researchers in this ﬁ  eld that RNA 
interference  [50] or the application of microRNA 
techniques [51,52] will eventually lead to breakthroughs 
in the correction of the increased risk factors conferred 
by the early onset AD mutations as well as the risk of AD 
associated with ApoEε4 alleles. However, such aspirations 
should not diminish present eﬀ  orts to pursue some of the 
current approaches described here.
In this respect, perhaps the most exciting prospect of 
the work reviewed here are the relatively large (23.7%) 
and statistically robust (Ρ ≤ 0.001) increases in sAPPα in 
our statin-treated asymptomatic subjects who were 
hetero  zygous for ApoEε4 when controlling for statin-
induced decreases in serum cholesterol levels [18]. If an 
increase in sAPPα is a prophylactic target for the 
prevention of AD, then these studies open the way for 
both augmentation studies of such eﬀ  ects and to compare 
the magnitude of the static eﬀ  ects observed here with 
those of other putative therapeutic agents.
Finally, we note that statin therapy has, in general, not 
been eﬀ   ective in treatment of established AD. For 
example, a 2002 randomized placebo-controlled 26-week 
trial of simvastatin in 44 patients with probable LOAD 
(genetic associations not speciﬁ  ed) found no signiﬁ  cant 
alteration of CSF Aβ40 or Aβ42 levels, but patients with 
mild AD showed a reduction in CSF Aβ40 that was 
correlated with a reduction of 24S-hydroxycholesterol 
[31]. Th   e Alzheimer’s Disease Cholesterol-Lowering Treat-
ment (ADCLT) trial examined the eﬀ  ects of atorvastatin 
over the course of 1 year in 98 individuals with mild to 
moderate LOAD and found hyper  choles  terolemic 
ApoEε4 carriers with mild to moderate AD were most 
likely to show modest beneﬁ  ts on the ADAS-Cog after 6 
months of treatment [53], but no such positive result was 
found in the much larger LEADe study encompassing 
640 patients over 72 weeks [54]. Similarly, no reduction 
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performance was found among the 5,804 participants 
aged 72 to 80 years with pronounced vascular risks in the 
PROSPER study randomized to either receive pravastatin 
or placebo over a 3-year period of observation [55]. A 
recent Cochrane review update has therefore maintained 
its conclusion that statin therapy is of no proven beneﬁ  t 
for the prevention of AD [56]. However, none of these 
negative results of statin therapy in established AD or in 
the very elderly with severe vascular risk factors excludes 
the possibility that statins must be started before 
neurodegenerative processes are well under way to be 
eﬀ  ective in reducing risk of AD.
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